1752 — Nang Kuang Pharmaceutical Co Cashflow Statement
0.000.00%
Last trade - 00:00
- TWD4.50bn
- TWD4.73bn
- TWD2.15bn
- 63
- 43
- 31
- 40
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 251 | 224 | 235 | 411 | 214 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 10.6 | 15.6 | 26.9 | -75.9 | 142 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -68.1 | -273 | 115 | -142 | -195 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 386 | 151 | 557 | 369 | 343 |
Capital Expenditures | -64 | -73.2 | -160 | -94.2 | -301 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -12.3 | -38.8 | -132 | -15.7 | -28.8 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Change in Net Investments | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -76.2 | -112 | -291 | -110 | -330 |
Financing Cash Flow Items | — | 50 | 0 | 30.3 | 0.056 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -94.6 | -164 | -114 | -275 | -35.8 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 215 | -125 | 151 | -15.9 | -22.7 |